Theravance Biopharma, Inc. Increase (Decrease) in Income Taxes Receivable
Theravance Biopharma, Inc. (TBPH) reported Increase (Decrease) in Income Taxes Receivable of $258.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2022-02-28
- Theravance Biopharma, Inc. increase (decrease) in income taxes receivable for the quarter ending 2020-12-31 was $295.00K.
- Theravance Biopharma, Inc. increase (decrease) in income taxes receivable for the quarter ending 2020-09-30 was -$337.00K.
- Theravance Biopharma, Inc. increase (decrease) in income taxes receivable for the quarter ending 2019-12-31 was $0.00.
- Theravance Biopharma, Inc. increase (decrease) in income taxes receivable for the quarter ending 2019-09-30 was $0.00.
- Theravance Biopharma, Inc. increase (decrease) in income taxes receivable for fiscal 2020 was $258.00K, a 93.03% decline from fiscal 2019.
- Theravance Biopharma, Inc. increase (decrease) in income taxes receivable for fiscal 2019 was $3.70M.
- Theravance Biopharma, Inc. increase (decrease) in income taxes receivable for fiscal 2018 was -$8.19M, a 203.81% decline from fiscal 2017.
- Theravance Biopharma, Inc. increase (decrease) in income taxes receivable for fiscal 2017 was $7.89M.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2020-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$42.00K derived: sum of 2 quarters · filed 2022-02-28 | $258.00K 10-K · filed 2022-02-28 | |
| 2020-09-30 | -$337.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$37.00K 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | $300.00K 10-Q · filed 2020-08-10 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $3.70M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.70M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $3.70M 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | -$3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$3.10M derived: sum of 2 quarters · filed 2021-02-26 | -$3.10M derived: sum of 3 quarters · filed 2021-02-26 | -$8.19M 10-K · filed 2021-02-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | -$5.09M 10-Q · filed 2019-11-08 | -$5.09M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$5.09M 10-Q · filed 2019-08-05 | -$5.09M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2018-03-31 | -$5.09M 10-Q · filed 2019-05-10 | -$5.09M derived: sum of 2 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $7.89M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $7.89M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $0.00 10-K · filed 2018-02-28 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-08 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |